286 related articles for article (PubMed ID: 32451369)
1. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
[TBL] [Abstract][Full Text] [Related]
2. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
[TBL] [Abstract][Full Text] [Related]
3. The Hippo pathway member Nf2 is required for inner cell mass specification.
Cockburn K; Biechele S; Garner J; Rossant J
Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
[TBL] [Abstract][Full Text] [Related]
4. Two Hippo signaling modules orchestrate liver size and tumorigenesis.
Qi S; Zhong Z; Zhu Y; Wang Y; Ma M; Wang Y; Liu X; Jin R; Jiao Z; Zhu R; Sha Z; Dang K; Liu Y; Lim DS; Mao J; Zhang L; Yu FX
EMBO J; 2023 Jun; 42(11):e112126. PubMed ID: 36919851
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators.
Lavado A; He Y; Paré J; Neale G; Olson EN; Giovannini M; Cao X
Development; 2013 Aug; 140(16):3323-34. PubMed ID: 23863479
[TBL] [Abstract][Full Text] [Related]
7. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of Motin family proteins in NF2-deficient cells prevents full activation of YAP/TAZ and rapid tumorigenesis.
Wang Y; Zhu Y; Gu Y; Ma M; Wang Y; Qi S; Zeng Y; Zhu R; Wang X; Yu P; Xu J; Shu Y; Yu FX
Cell Rep; 2021 Aug; 36(8):109596. PubMed ID: 34433060
[TBL] [Abstract][Full Text] [Related]
9. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.
Basu-Roy U; Bayin NS; Rattanakorn K; Han E; Placantonakis DG; Mansukhani A; Basilico C
Nat Commun; 2015 Apr; 6():6411. PubMed ID: 25832504
[TBL] [Abstract][Full Text] [Related]
10. A critical role for NF2 and the Hippo pathway in branching morphogenesis.
Reginensi A; Enderle L; Gregorieff A; Johnson RL; Wrana JL; McNeill H
Nat Commun; 2016 Aug; 7():12309. PubMed ID: 27480037
[TBL] [Abstract][Full Text] [Related]
11. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
12. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ.
Yi J; Lu L; Yanger K; Wang W; Sohn BH; Stanger BZ; Zhang M; Martin JF; Ajani JA; Chen J; Lee JS; Song S; Johnson RL
Hepatology; 2016 Nov; 64(5):1757-1772. PubMed ID: 27531557
[TBL] [Abstract][Full Text] [Related]
13. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC.
Choi W; Kim J; Park J; Lee DH; Hwang D; Kim JH; Ashktorab H; Smoot D; Kim SY; Choi C; Koh GY; Lim DS
Cancer Res; 2018 Jun; 78(12):3306-3320. PubMed ID: 29669762
[TBL] [Abstract][Full Text] [Related]
14. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
[TBL] [Abstract][Full Text] [Related]
15. β1 integrin-dependent Rac/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2/merlin.
Sabra H; Brunner M; Mandati V; Wehrle-Haller B; Lallemand D; Ribba AS; Chevalier G; Guardiola P; Block MR; Bouvard D
J Biol Chem; 2017 Nov; 292(47):19179-19197. PubMed ID: 28972170
[TBL] [Abstract][Full Text] [Related]
16. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.
Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY
Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213
[TBL] [Abstract][Full Text] [Related]
17. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.
Qi S; Zhu Y; Liu X; Li P; Wang Y; Zeng Y; Yu A; Wang Y; Sha Z; Zhong Z; Zhu R; Yuan H; Ye D; Huang S; Ling C; Xu Y; Zhou D; Zhang L; Yu FX
Mol Cell; 2022 May; 82(10):1850-1864.e7. PubMed ID: 35429439
[TBL] [Abstract][Full Text] [Related]
18. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.
Li H; Gumbiner BM
Mamm Genome; 2016 Dec; 27(11-12):556-564. PubMed ID: 27601049
[TBL] [Abstract][Full Text] [Related]
19. Integrin signalling regulates YAP and TAZ to control skin homeostasis.
Elbediwy A; Vincent-Mistiaen ZI; Spencer-Dene B; Stone RK; Boeing S; Wculek SK; Cordero J; Tan EH; Ridgway R; Brunton VG; Sahai E; Gerhardt H; Behrens A; Malanchi I; Sansom OJ; Thompson BJ
Development; 2016 May; 143(10):1674-87. PubMed ID: 26989177
[TBL] [Abstract][Full Text] [Related]
20. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
